Abbott (ABT) Stock Price Prediction 2027: Analyst Targets, Q1 2026 Earnings & Bull/Bear Scenarios

Abbott Laboratories closed at $95.47 on April 16, 2026 — its lowest level in twelve months and roughly 31% below the 52-week high of $139.06. The selloff accelerated after Q1 2026 earnings dropped the same afternoon, with the stock sliding another 6% as management cut full-year adjusted EPS guidance by $0.20 to absorb dilution from the just-closed $21 billion Exact Sciences acquisition. Wall Street’s reaction confused the longer-term story: 15 of 17 covering analysts rate ABT a Buy or Strong Buy, with zero Sell ratings, and a consensus 12-month target of $134.29 — implying 40% upside per Stock Analysis analyst forecast. The real question for 2027 is not whether Abbott recovers, but how quickly. Medical Devices just posted a twelfth consecutive quarter of double-digit growth, the FreeStyle Libre diabetes franchise is on track for $10 billion in annual revenue by 2028, and the company raised its quarterly dividend for the 54th consecutive year in December. The counterweight is a pending mountain of preterm infant formula litigation that Abbott is now lobbying Congress to contain. Those two storylines — compounding medical-device growth versus contingent liability overhang — will define where ABT trades by year-end 2027.

Last updated: April 17, 2026 at 12:15 PM ET. Price via Massive Market Data (ABT previous-day close). Next catalyst: second-quarter 2026 earnings in mid-July.

ABT Stock Price Snapshot

Source: Stock Analysis and Stock Analysis analyst forecast. Q1 2026 results: Abbott Q1 2026 earnings release.

Q1 2026 Earnings Breakdown

Abbott reported Q1 2026 revenue of $11.164B, up 7.8% on a reported basis and 3.7% organic. Adjusted diluted EPS came in at $1.15, up 6% year-over-year and within the guided range. The headline numbers were fine. The guidance update was not.

Management cut full-year 2026 adjusted EPS guidance to $5.38 to $5.58, down from the prior $5.55 to $5.80 range, to absorb roughly $0.20 of near-term dilution from the $21 billion Exact Sciences acquisition that closed March 23. Organic growth guidance was maintained at 6.5% to 7.5%, and the deal is expected to add approximately $3 billion of incremental 2026 revenue while pressuring short-term earnings as integration costs roll through the P&L. The market read the cut as weaker than expected and sold the stock.

Segment-Level Detail

Medical Devices: $5.539B (+13.2%). The twelfth consecutive quarter of double-digit growth. The breadth inside the segment is the story, not any single product. Electrophysiology grew 16.7% as the newly FDA-approved Volt pulsed field ablation system began contributing. Diabetes Care hit $2.080B on continued FreeStyle Libre penetration. Rhythm Management jumped 17% driven by AVEIR dual-chamber leadless pacemakers. Heart Failure added 14.6%. Structural Heart grew high single digits as TriClip continued to ramp.

Established Pharmaceuticals: $1.426B (+13.2%). Branded generics in emerging markets — an underappreciated part of Abbott’s portfolio. Consistent double-digit growth with limited patent cliff exposure.

Diagnostics: $2.180B (+6.1%). The segment finally lapped most of the COVID-19 testing rolloff. Core Lab, Rapid Diagnostics, and Molecular grew low-to-mid single digits. The Exact Sciences deal will materially reshape this segment’s 2027 profile.

Nutrition: $2.017B (-6.0%). The weakest segment and, in the near term, the hardest to fix. Demand for Similac and PediaSure remains below the pre-recall baseline, formulary decisions influenced by preterm infant litigation have reduced hospital channel sales, and international mix is unfavorable. Management flagged new product launches planned for later in 2026 — the question is whether they show up in the P&L before year-end 2027.

Abbott 2027 Price Prediction

The range of plausible outcomes for ABT by year-end 2027 is unusually wide, which is part of what makes the setup interesting at $95.47. Three specific scenarios are worth laying out with the math, not just the narrative.

Base case: $125 to $135 by end of 2027. This assumes Abbott delivers the midpoint of current guidance ($5.48 adjusted EPS in 2026) and grows adjusted EPS roughly 9 to 11% in 2027 to approximately $6.05 to $6.20 as Exact Sciences dilution reverses and Medical Devices growth continues. Applying the current forward P/E of 17x to the 2028 consensus EPS gives a base-case target of roughly $125 to $135 — essentially matching the current 24/7 Wall St. and analyst consensus targets.

Bull case: $145 to $155. Multiple expansion back to the healthcare-compounder P/E of 20-21x (where Abbott traded in 2023) on FreeStyle Libre exceeding $10 billion run-rate earlier than expected, Volt capturing double-digit share of the U.S. pulsed field ablation market, Exact Sciences integration delivering synergies ahead of schedule, and NEC litigation settling within manageable reserves. This is the scenario where the 54-year dividend streak and the 13% Medical Devices growth rate get re-rated as structural compounding rather than a penalized healthcare average.

Bear case: $95 to $110. Flat to modestly higher from current levels. This scenario contemplates: Nutrition segment revenue remaining down low-single-digits through 2027, a large adverse NEC verdict or multi-billion-dollar settlement that forces a reserve build, Exact Sciences synergies delayed, FreeStyle Libre facing more aggressive Dexcom competition in the U.S. intensive insulin market, and a general healthcare sector multiple compression. Under these conditions, 17x trailing EPS of $5.75 lands around $98 — essentially flat from today’s price. That is the outcome the market is currently pricing in; anything better than Nutrition staying flat or the NEC litigation settling within reserves would re-rate the stock higher.

The Bull Case for ABT by 2027

Four things have to go right for the bull case. All four are tracking on schedule.

FreeStyle Libre keeps compounding. Q1 2026 Diabetes Care revenue of $2.080B annualizes close to $8.3 billion. Abbott’s 2028 target of $10 billion in annual Libre revenue requires roughly 10% annual growth from here — well below the 13.8% segment growth just posted. The GLP-1 weight-loss drug tailwind expands the addressable market: non-diabetic patients on semaglutide or tirzepatide increasingly use CGMs to monitor glucose response. Abbott’s Lingo consumer biosensor, launched in 2024, positions the company for the wellness-facing side of that market.

Volt PFA captures meaningful U.S. share. The December 22, 2025 FDA approval of the Volt pulsed field ablation system puts Abbott into the fastest-growing atrial fibrillation treatment category. Pulsed field ablation is expected to take most of the $6 billion U.S. cardiac ablation market from older radiofrequency approaches by 2028, according to MedTech Dive. Abbott is late relative to Boston Scientific’s Farapulse and Medtronic’s PulseSelect, but the Electrophysiology segment already grew 16.7% in Q1 2026 before Volt meaningfully contributed.

Exact Sciences integration delivers synergies. The $21 billion deal that closed March 23, 2026 adds Cologuard, Oncotype DX, and a growing screening pipeline to Abbott’s Diagnostics portfolio. The near-term dilution was telegraphed. The harder question is whether Abbott can leverage its international diagnostics channel to grow Exact Sciences assets outside the U.S. faster than Exact could standalone. Management’s track record with the 2017 St. Jude Medical integration — still cited as one of the cleaner large medtech deals of the past decade — sets a credible base rate.

Multiple re-rates toward healthcare-compounder peers. At 14.65x forward EV/EBITDA, ABT trades at a 16% discount to Johnson & Johnson and a 25% discount to Danaher. If the market starts pricing Abbott for its Medical Devices growth rate rather than its blended average, a move to 17x closes most of that gap and produces $130+ on 2027 EPS of $6.10 with no growth acceleration required. For context, see how we framed similar multiple-compression setups in our best AI stocks analysis.

The Bear Case: NEC Litigation & Guidance Cut

The bear case is less about what Abbott does wrong and more about what could be done to Abbott. Two overhangs deserve close attention.

NEC preterm formula litigation. Roughly 782 lawsuits are pending against Abbott in the federal MDL consolidated before Judge Rebecca Pallmeyer in the Northern District of Illinois. These claims allege that Similac Special Care and related preterm products increase the risk of necrotizing enterocolitis. In April 2026, a Cook County jury awarded $70 million against Abbott ($53 million compensatory plus $17 million punitive). A prior Missouri verdict hit the company with $95 million compensatory plus $400 million punitive, later reduced on appeal. The federal MDL is scheduled for additional bellwether trials in August 2026, November 2026, and February 2027.

Abbott’s response has been unusually aggressive. In December 2025, the company began lobbying Congress for a statutory liability shield — framing preterm formula as a public-health necessity that should not face tort exposure. The fact that Abbott is pursuing legislative relief signals the company views this as a multi-billion-dollar tail risk. Successful lobbying would be the best possible outcome for ABT shareholders; failure and a large MDL settlement would be the worst.

The guidance cut math. The Exact Sciences dilution is real. Adjusted EPS guidance moved from $5.55–$5.80 to $5.38–$5.58 — a $0.20 reduction at the midpoint. At Abbott’s current 17x forward multiple, that alone accounts for roughly $3.40 of share price compression. The April 16 selloff arguably overshot, but the market is not wrong that consensus estimates will need to come down through the next two quarters as analysts model integration costs more precisely.

Nutrition segment drag. Down 6% in Q1 2026 after declining 8.9% in Q4 2025. Management has flagged new product launches for later this year, but the Similac brand equity damage from the 2022 recall plus the drag from NEC-driven hospital formulary changes is taking longer to repair than initially expected. A Nutrition segment that returns to flat growth by late 2027 is a reasonable base case; one that accelerates to 4-5% growth is the bull case; one that stays down mid-single-digits is the bear. For broader stock market context, see our live stock market analysis.

Abbott vs Johnson & Johnson, Medtronic, Danaher

The valuation table is the most useful lens on Abbott right now. Every major healthcare-diversified peer trades at a premium on at least one metric, and ABT posts the highest Medical Devices growth rate of the group.

Forward P/E: Abbott 17.0x, Medtronic 14.7x, Johnson & Johnson 19.9x, Danaher 23.1x. EV/EBITDA: Abbott 14.7x, Medtronic 13.7x, Johnson & Johnson 17.4x, Danaher 19.4x. Dividend yield: Abbott 2.6%, Medtronic 3.3%, Johnson & Johnson 2.2%, Danaher 0.8%. Data via Stock Analysis.

Medtronic is cheaper and pays more income. It is also growing revenue at approximately half Abbott’s pace. Johnson & Johnson carries the larger pharma overhang with Stelara patent expiry and has not posted a Medical Devices growth rate approaching 13% in any recent quarter. Danaher is the highest-multiple peer because it is genuinely the highest-quality compounder, but at 23x forward earnings, the setup for multiple re-rating is inverted — any growth miss compresses the multiple rather than expanding it.

Abbott sits in the middle on valuation and at the top on Medical Devices growth. That combination is what produces asymmetric upside in the $130-145 range over 2027 if the litigation overhang partially resolves.

The Dividend King Foundation

Abbott raised its quarterly dividend to $0.63 per share on December 12, 2025 — the 54th consecutive year of increases and the 408th uninterrupted quarterly payment since 1924. That track record places ABT among a small group of companies (along with Procter & Gamble, 3M, and Coca-Cola) with genuine Dividend King status. The annualized payout of $2.52 per share produces a yield of approximately 2.6% at current prices, well above the S&P 500 average.

The payout ratio tells the more interesting story. On trailing GAAP EPS it looks stretched at 68%, but on adjusted EPS — the figure that drives capital allocation decisions — the payout sits closer to 49%. That gives Abbott meaningful room to continue raising the dividend through 2027 even in the bear-case scenario, and also preserves capacity for opportunistic buybacks. A second wave of buyback activity is the most underappreciated potential catalyst for 2027: Abbott’s balance sheet can support it, and the share price is unambiguously discounted.

For income-focused investors building a core healthcare position, the 54-year streak is the safety net. For total-return investors, it is the free option — downside protection while waiting for Medical Devices compounding and multiple re-rating to play out.

Catalysts to Watch Through 2027

Q2 2026 earnings (mid-July 2026). The first full quarter reflecting Exact Sciences ownership. Watch for updated synergy targets, integration progress, and any revision to the $0.20 dilution estimate. A smaller-than-expected dilution would mark the earnings inflection.

NEC bellwether trials (August 2026, November 2026, February 2027). Each outcome resets the market’s litigation probability distribution. A string of defense verdicts would likely trigger multiple re-rating well before any global settlement. The opposite outcome — plaintiff wins with large punitive awards — forces reserve builds that compress EPS.

Congressional action on preterm formula liability shield. Abbott’s lobbying push is a multi-year effort. Any bill movement, whether favorable or not, will move ABT measurably. Watch for legislation tied to appropriations bills or public-health packages.

Volt PFA quarterly revenue disclosure. Abbott does not break out individual product revenue, but Electrophysiology subsegment growth rates will reveal whether Volt is accelerating share capture. A sustained 20%+ growth rate through 2026 would mark a clear bull-case confirmation.

FreeStyle Libre international expansion. Libre is the global CGM leader by patient count but trails Dexcom in U.S. intensive insulin users. Pricing and reimbursement wins in emerging markets through 2027 determine whether the $10 billion 2028 run-rate target gets beaten or missed.

Federal Reserve rate path. Abbott, like most dividend compounders, benefits from a falling-rate environment that compresses bond yields and pulls income-seeking capital back toward high-quality equities. A Fed pivot to multiple rate cuts through 2027 is a tailwind; a sustained higher-for-longer scenario is a headwind.

The 24/7 Wall St. long-form analysis published April 17, 2026 arrived at a 2027 target of $125.10 with 24% upside from its starting price. That lands squarely inside the base-case range laid out above. The distinction this pillar adds: the bull case is not just “more of the same” — it requires the multiple to expand alongside the earnings. The bear case is not just “litigation” — it is litigation combined with Nutrition segment drag persisting into 2027. Separating those two bear vectors is what makes Abbott’s current setup a risk-defined position rather than a pure directional bet.

This is a developing story. Abbott (ABT) prices are updated as market conditions change. Last updated: April 17, 2026 at 12:15 PM ET. Price data via Massive Market Data API (ABT previous-day close) and Q1 2026 figures from Abbott IR. Next scheduled update: Q2 2026 earnings release in mid-July 2026.